Concerto Biosciences CEO Cheri Ackerman (L) and CSO Jared Kehe

'Rule­book of mi­cro­bial ecol­o­gy': Pi­anists launch Con­cer­to to treat eczema, pro­tect crops and get rid of BO

The mi­cro­bio­me world, at least in drug R&D, has had some hic­cups this year, with Flag­ship’s Kalei­do Bio­sciences shut­ting down and DermBiont piv­ot­ing away from the world of mi­crobes, but there’s al­ways room for new in­no­va­tion.

In steps Con­cer­to Bio­sciences, which came out with a $23 mil­lion Se­ries A this week. Mer­ck KGaA’s VC arm, Sa­far Part­ners and Hori­zons Ven­tures are all back­ing the Cam­bridge, MA start­up hop­ing to treat atopic der­mati­tis, pro­tect crops and get rid of bad odor in those sweaty armpits.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.